Home » Newsletters » BioWorld Science

BioWorld Science

July 18, 2013

View Archived Issues

Novartis develops new apoptosis regulators

CHF-5074 shows promising clinical efficacy in MCI

Gene linked to albuminuria in rat model

Tau-based immunotherapy for Alzheimer's disease described

LASSbio-1359 reverses development of PAH in rats

Dupilumab leads to improvements in eosinophilic asthma in phase IIa study

Daiichi Sankyo reports on in vivo studies of beta-amyloid peptide vaccine

Researchers develop novel transgenic mouse models of migraine-related disorders

Phase II study planned for CF-101 in uveitis

DSMB approves progress in three Advanced Cell Technology trials

FDA grants orphan designation to LJPC-0712 in Niemann-Pick type C disease

Adynxx receives FDA fast track designation for chronic pain treatment AYX1

ELND-005 granted FDA fast track designation for NPS in Alzheimer's disease

Spectrum Pharmaceuticals gains Marqibo with Talon Therapeutics acquisition

FDA accepts resubmission of NDA for Northera

Alkermes commences phase II study of broad-spectrum oral antipsychotic candidate

Compugen reveals new infrastructure platform for antibody discovery

New cationic polypeptides designed at the University of Minnesota

Rexahn in-licenses oncology drug delivery platform from University of Maryland, Baltimore

Novira Therapeutics prepares novel agents for HBV infection

Team of researchers in Brazil develop new vaccines for Brucella infection

Janssen and Pepscan patent novel polypeptide HIV fusion inhibitors

Novel lisuride analogues disclosed by MAP Pharmaceuticals, now part of Allergan

Alexion commences phase I trial of treatment candidate for MoCD

Recruitment begins in Boehringer Ingelheim's phase I trial of BI-409306

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...